SecBot SecBot
8-K ·Filed Nov 5, 2026

XRAY

DENTSPLY SIRONA Inc.
BEARISH
Impact 6/10
Horizonweeks Processed11d 11h ago SEC0000818479-26-000285
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The broad-based revenue decline across three of four segments and the lowered FY guidance signal ongoing demand weakness in dental equipment and supplies. Watch for further restructuring actions and whether the Wellspect Healthcare growth trajectory can offset declines in core dental segments.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Dentsply Sirona reported Q3 2026 net sales of $836M, down 7.6% YoY, and adjusted EPS of $0.29, down 29.4% YoY, missing consensus estimates on both revenue ($861.7M) and EPS ($0.31). The company lowered its FY2026 outlook to approximately $3.5B in net sales and adjusted EPS of $1.20-$1.30, excluding a $0.17 one-time benefit from tariff refunds. All major segments except Wellspect Healthcare declined, with Connected Technology Solutions down 11.0% and Orthodontic and Implant Solutions down 16.6%.

Key Financial Metrics

EPS (Adj.)
$0.29
est $0.31 · -6.5% · GAAP: $-0.01
Revenue
$836.0M
est $861.7M · -3.0% · -7.6% YoY
Rating
miss
Guidance
approximately $3.5 billion
lowered
Free Cash Flow
$0.00
Gross Margin
52.9%

Key Facts

  • Q3 2026 net sales of $836M, down 7.6% YoY from $904M
  • Adjusted EPS of $0.29, down 29.4% YoY from $0.42
  • GAAP diluted loss per share of ($0.01) vs ($2.14) in Q3 2025
  • FY2026 outlook lowered to approximately $3.5B in net sales and adjusted EPS of $1.20-$1.30
  • Consensus estimates were EPS $0.31 and revenue $861.7M
  • Wellspect Healthcare was the only growing segment, with record quarterly sales up 10.1% YoY
  • Connected Technology Solutions sales fell 11.0%, Orthodontic and Implant Solutions fell 16.6%
  • Operating cash flow was $32M vs $79M in Q3 2025; free cash flow was $0M vs $40M
  • Company repurchased 1.2M shares for $13M in Q3 2026

Financial Impact

Revenue miss of ~$25.7M vs consensus; adjusted EPS miss of $0.02 vs consensus; FY guidance lowered from $3.5B-$3.6B to ~$3.5B and adjusted EPS from $1.40-$1.50 to $1.20-$1.30

revenueepsguidancecash flow

Segment Breakdown

SegmentRevenueGrowth
Connected Technology Solutions$230.0M-11.0%
Essential Dental Solutions$343.0M-4.0%
Orthodontic and Implant Solutions$171.0M-16.6%
Wellspect Healthcare$92.0M+10.1%

Risk Factors

  • Continued revenue decline in Connected Technology Solutions and Orthodontic and Implant Solutions
  • Lowered FY2026 adjusted EPS guidance implies a weak Q4 outlook
  • Operating cash flow deterioration and near-zero free cash flow
  • Restructuring and transformation costs continue to pressure margins

Market Snapshot

Exchange
Nasdaq
Sector
Dental Equipment & Supplies
Analyst Consensus
35% bullish (23 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000818479-26-000285
Document: xray-20261105.htm0000818479-26-000285
Document: 0000818479-26-000285-index-headers.html0000818479-26-000285
Document: 0000818479-26-000285-index.html0000818479-26-000285
Document: 0000818479-26-000285.txt0000818479-26-000285
8-K Data (Synthetic)0000818479-26-000285

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026